Compare SLQT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLQT | IKT |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 220.5M |
| IPO Year | 2020 | 2020 |
| Metric | SLQT | IKT |
|---|---|---|
| Price | $0.81 | $1.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.88 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 2.2M | 862.5K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.00 | 57.76 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,526,594,000.00 | N/A |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | $7.19 | ★ N/A |
| Revenue Growth | ★ 15.50 | N/A |
| 52 Week Low | $0.56 | $1.33 |
| 52 Week High | $2.77 | $2.26 |
| Indicator | SLQT | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 67.39 |
| Support Level | $0.79 | $1.63 |
| Resistance Level | $0.94 | $2.13 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 4.92 | 78.62 |
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.